The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 03, 2012
Filed:
Apr. 19, 2007
Thomas Daniel Aicher, Superior, CO (US);
Zhaogen Chen, Shanghai, CN;
Ronald Jay Hinklin, Longmont, CO (US);
Gary Alan Hite, Indianapolis, IN (US);
Alexei Pavlovych Krasutsky, Zionsville, IN (US);
Renhua LI, Fishers, IN (US);
Jefferson Ray Mccowan, Indianapolis, IN (US);
Ashraf Saeed, Westfield, IN (US);
Nancy June Snyder, Lizton, IN (US);
James Lee Toth, Knightstown, IN (US);
Owen Brendan Wallace, Westfield, IN (US);
Leonard Larry Winneroski, Jr., Greenwood, IN (US);
Yanping Xu, Noblesville, IN (US);
Jeremy Schulenburg York, Noblesville, IN (US);
Thomas Daniel Aicher, Superior, CO (US);
Zhaogen Chen, Shanghai, CN;
Ronald Jay Hinklin, Longmont, CO (US);
Gary Alan Hite, Indianapolis, IN (US);
Alexei Pavlovych Krasutsky, Zionsville, IN (US);
Renhua Li, Fishers, IN (US);
Jefferson Ray McCowan, Indianapolis, IN (US);
Ashraf Saeed, Westfield, IN (US);
Nancy June Snyder, Lizton, IN (US);
James Lee Toth, Knightstown, IN (US);
Owen Brendan Wallace, Westfield, IN (US);
Leonard Larry Winneroski, Jr., Greenwood, IN (US);
Yanping Xu, Noblesville, IN (US);
Jeremy Schulenburg York, Noblesville, IN (US);
Eli Lilly and Company, Indianapolis, IN (US);
Abstract
The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β-HSD type 1 activity.